Voyager Therapeutics (VYGR) EPS (Weighted Average and Diluted) (2018 - 2026)

Voyager Therapeutics has disclosed EPS (Weighted Average and Diluted) across 9 years of filings, most recently posting -$0.47 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.47, up 11.32% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.98 (down 34.69% YoY), and the FY2025 annual result was -$2.04, down 80.53% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.47 for Q1 2026 at Voyager Therapeutics, roughly flat from -$0.47 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.94 in Q1 2023 to a low of -$0.62 in Q4 2022.
• The 5-year median for EPS (Weighted Average and Diluted) is -$0.47 (2025), against an average of -$0.11.
• Across the five-year window, EPS (Weighted Average and Diluted) tumbled 513.33% in 2022 and soared 625.0% in 2023, its largest moves.
• Voyager Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.62 in 2022, then soared by 291.94% to $1.19 in 2023, then plunged by 150.42% to -$0.6 in 2024, then climbed by 21.67% to -$0.47 in 2025, then changed by 0.0% to -$0.47 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.47 (Q1 2026), -$0.47 (Q4 2025), and -$0.47 (Q3 2025), per Business Quant data.